dm+d

34486211000001108

New Medicines

ParsabivSecondary hyperparathyroidism in children aged 2 years and older on haemodialysis for end-stage kidney disease - add-on to standard care

Information

Parsabiv
Licence extension / variation
Amgen
Amgen

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials

Category

Activates calcium sensing receptor on parathyroid glands reducing PTH synthesis and secretion
Secondary hyperparathyroidism is seen in almost all patients with dialysis-dependent CKD. Most patients with CKD stage 5 develop SHPT [1]. Renal replacement therapy incidence in patients aged <16 years is 7.9 per million age related population (pmarp) [2].
Secondary hyperparathyroidism in children aged 2 years and older on haemodialysis for end-stage kidney disease - add-on to standard care
Intravenous